In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Curetis NV

www.curetis.com

Latest From Curetis NV

Pacts In Medtech: Glaukos To Distribute Saten's MicroShunt; Acell Signs Distribution Deals

Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in March and April 2019.

Pacts in Medtech Deals

Device Debut: Curetis' Unyvero Infectious Disease Tester Earns De Novo Clearance

FDA granted de novo clearance to Curetis' Unyvero "sample-to-answer" diagnostic system and the Lower Respiratory Tract Infection Application Cartridge, the company announced April 3. Unyvero works with the Unyvero LRT Application Cartridge to provides rapid infectious disease testing directly from aspirate samples in less than five hours. The FDA decision comes a day after the Singapore Health Sciences Authority approved Curetis' Unyvero BCU Cartridge.

Approvals In Vitro Diagnostics

Could First-Mover Advantage Make Curetis Ripe For The Picking By Dx Players?

German molecular diagnostics company Curetis may have missed its original forecast for a 2017 US launch of its flagship Unyvero infectious disease test platform, but CEO Oliver Schacht is confident that the all-clear from FDA is very close. When this crucial milestone is achieved, the firm will be the first in the US with a molecular diagnostic for lower respiratory tract infections. And the approval could increase Curetis' appeal as an acquisition target for larger diagnostics players.

In Vitro Diagnostics Infectious Diseases

Device/Diagnostics Quarterly Deal Statistics, Q4 2015

At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.

Medical Device Deals
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Curetis AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Curetis NV
  • Senior Management
  • Oliver Schacht, CEO
    Andreas Boos, CTO
    Heiko Schorr, Dir., Fin.
    Helmut Hilbert, PhD, Head, Bus. Dev.
    Achim Plum, CBO
  • Contact Info
  • Curetis NV
    Phone: (49) 7031 49195-10
    Max-Eyth-Str. 42
    Holzgerlingen, 71088
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register